Stock Quote Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bicycle Therapeutics Plc ADR (NQ: BCYC ) 28.45 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 28.45 Bid (Size) 26.55 (2) Ask (Size) 28.92 (1) Prev. Close 28.45 Today's Range 28.45 - 28.45 52wk Range 12.08 - 51.93 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year Top News More News Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium January 11, 2023 From Bicycle Therapeutics plc Via Business Wire Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer January 04, 2023 From Bicycle Therapeutics plc Via Business Wire Performance YTD -5.17% -5.17% 1 Month -5.17% -5.17% 3 Month +16.74% +16.74% 6 Month +12.18% +12.18% 1 Year -42.33% -42.33% More News Read More Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting November 10, 2022 From Bicycle Therapeutics Via Business Wire Recap: Bicycle Therapeutics Q3 Earnings November 03, 2022 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 January 05, 2023 Via Benzinga Looking Into Bicycle Therapeutics's Return On Capital Employed November 23, 2022 Via Benzinga Expert Ratings for Bicycle Therapeutics August 22, 2022 Via Benzinga Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update November 08, 2022 From Bicycle Therapeutics Via Business Wire Bicycle Therapeutics to Participate in Upcoming Investor Conferences November 04, 2022 From Bicycle Therapeutics plc Via Business Wire Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 03, 2022 From Bicycle Therapeutics plc Via Business Wire Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program October 10, 2022 From Bicycle Therapeutics plc Via Business Wire Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics September 19, 2022 From Bicycle Therapeutics plc Via Business Wire Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary September 07, 2022 Via Benzinga Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors September 07, 2022 From Bicycle Therapeutics plc Via Business Wire Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference September 06, 2022 From Bicycle Therapeutics plc Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022 August 31, 2022 Via Benzinga Looking Into Bicycle Therapeutics's Return On Capital Employed August 22, 2022 Via Benzinga Bicycle Therapeutics: Q2 Earnings Insights August 04, 2022 Via Benzinga Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update August 04, 2022 From Bicycle Therapeutics plc Via Business Wire Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides August 02, 2022 From Bicycle Therapeutics plc Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022 July 28, 2022 Via Benzinga Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry July 12, 2022 From Bicycle Therapeutics plc Via Business Wire Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration July 12, 2022 From Bicycle Therapeutics plc Via Business Wire Where Bicycle Therapeutics Stands With Analysts July 06, 2022 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session June 24, 2022 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
